A subset of patients with severe COVID-19 develop profound inflammation and multi-organ
dysfunction consistent with a “Cytokine Storm Syndrome” (CSS). In this review we compare …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the …

This article introduces the analytical framework of the collection on the performance of the
EU in international institutions and summarizes its main findings. We focus on the role of the …

Background: Patients with immune-mediated diseases on immunosuppressive therapies have
more infectious episodes than healthy individuals, yet vaccination practices by physicians …

Objective To assess the efficacy, tolerability, and safety of cannabinoids (phyto‐ and
syntheto‐) in the management of rheumatic diseases. Methods Multiple databases, including …

Data suggest that interleukin (IL)-6 blockade could reduce mortality in severe COVID-19, yet
IL-6 is only modestly elevated in most patients. Chen et al. describe the role of soluble …

Objective To determine the comparative effectiveness of oral versus subcutaneous
methotrexate (MTX) as initial therapy for patients with early rheumatoid arthritis (ERA). Methods …

Objective Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy,
their use is associated with immune toxicities referred to as immune-related adverse events (…

Objective To evaluate the reliability of concurrent flare identification using 3 methods (patient,
rheumatologist and Disease Activity Score (DAS)28 criteria), and construct validity of …

Background Arthritis pain is reported as one of the most common reasons for persons using
medical herbal cannabis in North America. “Severe arthritis” is the condition justifying legal …